RCUS
Arcus Biosciences
–
Index: NYSE; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 1.13B; Volume: 429.25K; AvgVol 3m: 557.41K; Beta: –;
Cost estimate:
P/E: –; EPS: -2.44; EPS growth quarter/prev quarter: -44.70%;
EPS growth this year: -34.90%; EPS growth past 5 years: ;
EPS ttm: -2.44;
P/S: 78.00; P/B: 02.02; P/Cashflow: 2.53; P/FCF: ;
Sales: 15.00M; Sales growth quarter/prev quarter: 0.00%; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -41.50%; ROE – return on equity: -49.10%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 13.70%; Insider Transactions:0.55%;
Institutional Ownership: 57.00%; Institutional Transactions: 66.50%;
Data update: 07/10/2020.